Please use a PC Browser to access Register-Tadawul
UPDATE 1-Gilead to acquire Arcellx for $7.8 billion
Arcellx, Inc. ACLX | 114.39 | +0.09% |
Gilead Sciences, Inc. GILD | 144.99 | +0.42% |
Adds shares in first paragraph, deal details in paragraph 3
Feb 23 (Reuters) - Gilead Sciences GILD.O said on Monday it will buy cancer therapy developer Arcellx ACLX.O for an implied equity value of $7.8 billion, sending shares of Arcellx climbing 77.8% to $113.99 in premarket trading.
Gilead will pay $115 per share in cash at the deal's closing and one contingent value right of $5 per share, which is a premium of 87% to the stock's last close.


